Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Pulmonx
LUNG
Pulmonx
US Hospital Workflows Will Delay Progress Yet Recovery Will Follow
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.50
36.0% undervalued
intrinsic discount
16 Aug
US$1.60
Loading
1Y
-76.3%
7D
3.2%
Author's Valuation
US$2.5
36.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.5
36.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-61m
126m
2018
2020
2022
2024
2025
2026
2028
Revenue US$126.0m
Earnings US$15.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
24.62%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
9.50%
Calculation
US$15.65m
Earnings '28
x
9.45x
PE Ratio '28
=
US$147.97m
Market Cap '28
US$147.97m
Market Cap '28
/
45.93m
No. shares '28
=
US$3.22
Share Price '28
US$3.22
Share Price '28
Discounted to 2025 @ 9.57% p.a.
=
US$2.45
Fair Value '25
